Ajay Perumbeti, MD is Director of Transfusion Medicine, Co-director of the Infusion Center, and FACT Apherisis Collections and Medical Director in the Department of Pathology and Laboratory Medicine at Children’s Hospital Los Angeles. Dr. Perumbeti trained in pediatrics, pediatric hematology oncology, and transfusion medicine, at SUNY Syracuse, Children’s Hospital Los Angeles, Cincinnati Children’s Hospital, and Hoxworth Blood Center, respectively. His research interests are pediatric transfusion medicine, development of personalized blood and cellular therapeutics, and the role of HLA-G in pediatric disease.
Northeastern Ohio Univ. Med. College
State University of New York
State University of New York, Pediatrics
- Children's Hospital of Los Angeles (Hematology/Oncology/Transplantation) 2005-2006
- Cincinnati CHildren's Hospital Medical Center (Hematology/Oncology/Transplantation) 2006-2008
- Cincinnati Children's Hospital Medical Center (Hematology/Oncology/Transplantation) 2008-2009
- Hoxworth Blood Center, University of Cincinnati (Transfusion Medicine) 2011-2013
Pediatrics, Pediatric Hematology Oncology, and Transfusion Medicine; Pediatrics, American Board of Pediatrics, 2004-2014; Pediatric Hematology Oncology, American Board of Pediatrics, 2009-2016; Transfusion Medicine, American Board of Pathology, 2012-
Northeastern Ohio University Medical College
Medical Awards National Blood Foundation Travel Grant, National Blood Foundation, American Association of Blood Banks National Meeting, San Diego, CA, 2011; Procter Scholer, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008; Sickle Scholar, National Institute of Health, Cincinnati Children’s Hospital Medical Center Comprehensive Sickle Cell Center, Cincinnati, OH, 2007
1: Chang KH, Nayak RC, Roy S, Perumbeti A, Wellendorf AM, Bezold KY, Pirman M, Hill SE, Starnes J, Loberg A, Zhou X, Inagami T, Zheng Y, Malik P, Cancelas JA. Vasculopathy-associated hyperangiotensinemia mobilizes haematopoietic stem cells/progenitors through endothelial AT₂R and cytoskeletal dysregulation. Nat Commun. 2015 Jan 9;6:5914. PubMed PMID: 25574809; PubMed Central PMCID: PMC4293039.
2: Perumbeti A, Malik P. Therapy for beta-globinopathies: a brief review and
determinants for successful and safe correction. Ann N Y Acad Sci. 2010
Aug;1202:36-44. PubMed PMID:20712770.
3: Swensen JJ, Agarwal AM, Esquilin JM, Swierczek S, Perumbeti A, Hussey D, Lee M, Joiner CH, Pont-Kingdon G, Lyon E, Prchal JT. Sickle cell disease resulting from uniparental disomy in a child who inherited sickle cell trait. Blood. 2010 Oct 14;116(15):2822-5. Epub 2010 Jul 1. PubMed PMID: 20595515.
4: Perumbeti A, Malik P. Genetic correction of sickle cell anemia and
beta-thalassemia: progress and new perspective. ScientificWorldJournal. 2010 Apr 13;10:644-54. PubMed PMID: 20419277.
5: Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 2009 Aug 6;114(6):1174-85. Epub 2009 May 27. PubMed PMID: 19474450; PubMed Central PMCID: PMC2723013.